GALT logo

Galectin Therapeutics (GALT) Accounts Payable

Annual Accounts Payable

$6.43 M
+$2.54 M+65.32%

December 31, 2023

Summary

Performance

1-Year Change

+65.32%

3-Year Change

+397.76%

5-Year Change

+2065.32%

15-Year Change

+957.73%

GALT Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

60.79%
GALT annual accounts payable is higher than 60.79% of companies in Healthcare sector

High & Low

All-time High

$6.43 M
GALT annual accounts payable is currently at an all-time high

3-Year Low

$1.80 M
GALT annual accounts payable is currently +256.29% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
GALT previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 28, 2025
GALT next annual earnings announcement is scheduled for Mar 28, 2025

OtherGALTbalance sheetmetrics:

Annual Accounts Receivable

-
GALT annual accounts receivable value is unknown

Annual Total Liabilities

$88.44 M
GALT annual total liabilities is $88.44 million

Annual Total Assets

$28.20 M
GALT annual total assets is $28.20 million

Annual Current Assets

$27.71 M
GALT annual total current assets is $27.71 million

Quarterly Accounts Payable

$2.79 M
-$903.00 K-24.42%

September 30, 2024

Summary

Performance

3-Month Change

-24.42%

1-Year Change

+4.25%

3-Year Change

+45.8%

5-Year Change

+68.27%

GALT Quarterly Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

41.53%
GALT quarterly accounts payable is higher than 41.53% of companies in Healthcare sector

High & Low

All-time High

$6.43 M
GALT quarterly accounts payable is currently -56.54% below its historical high of $6.43 million

3-Year Low

$1.80 M
GALT quarterly accounts payable is currently +54.85% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
GALT previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 28, 2025
GALT next earnings announcement is scheduled for Mar 28, 2025

OtherGALTbalance sheetmetrics:

Quarterly Accounts Receivable

-
GALT quarterly accounts receivable value is unknown

Quarterly Total Liabilities

$121.45 M
GALT quarterly total liabilities is $121.45 million

Quarterly Total Assets

$28.97 M
GALT quarterly total assets is $28.97 million

Quarterly Current Assets

$28.67 M
GALT quarterly total current assets is $28.67 million

Accounts Payable Formula

Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers

GALT Accounts Payable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+65.3%+4.3%
3 y3 years+397.8%+45.8%
5 y5 years+2065.3%+68.3%

GALT Accounts Payable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+256.3%-56.5%+54.9%
5 y5-yearat high+397.8%-56.5%+1256.8%
alltimeall timeat high+5044.8%-56.5%+2667.3%

Galectin Therapeutics Accounts Payable History

DateAnnualQuarterly
Sep 2024
-
$2.79 M(-24.4%)
Jun 2024
-
$3.70 M(-2.6%)
Mar 2024
-
$3.80 M(-41.0%)
Dec 2023
$6.43 M(+65.3%)
$6.43 M(+139.9%)
Sep 2023
-
$2.68 M(+35.7%)
Jun 2023
-
$1.98 M(-22.6%)
Mar 2023
-
$2.55 M(-34.4%)
Dec 2022
$3.89 M(+115.5%)
$3.89 M(+65.4%)
Sep 2022
-
$2.35 M(-20.6%)
Jun 2022
-
$2.96 M(+55.5%)
Mar 2022
-
$1.91 M(+5.6%)
Dec 2021
$1.80 M(+39.7%)
$1.80 M(-5.8%)
Sep 2021
-
$1.92 M(+107.5%)
Jun 2021
-
$924.00 K(+141.9%)
Mar 2021
-
$382.00 K(-70.4%)
Dec 2020
$1.29 M(-22.2%)
$1.29 M(+87.0%)
Sep 2020
-
$691.00 K(+235.4%)
Jun 2020
-
$206.00 K(-68.8%)
Mar 2020
-
$660.00 K(-60.3%)
Dec 2019
$1.66 M(+459.3%)
$1.66 M(+369.2%)
Sep 2019
-
$354.00 K(-10.6%)
Jun 2019
-
$396.00 K(-11.6%)
Mar 2019
-
$448.00 K(+50.8%)
Dec 2018
$297.00 K(-51.2%)
$297.00 K(+73.7%)
Sep 2018
-
$171.00 K(-22.3%)
Jun 2018
-
$220.00 K(-80.9%)
Mar 2018
-
$1.15 M(+89.3%)
Dec 2017
$608.00 K(-33.2%)
$608.00 K(+266.3%)
Sep 2017
-
$166.00 K(-58.4%)
Jun 2017
-
$399.00 K(-70.4%)
Mar 2017
-
$1.35 M(+47.9%)
Dec 2016
$910.00 K(+103.1%)
$910.00 K(+39.6%)
Sep 2016
-
$652.00 K(-30.0%)
Jun 2016
-
$932.00 K(-28.9%)
Mar 2016
-
$1.31 M(+192.6%)
Dec 2015
$448.00 K(-50.6%)
$448.00 K(-51.8%)
Sep 2015
-
$929.00 K(+19.9%)
Jun 2015
-
$775.00 K(-15.9%)
Mar 2015
-
$922.00 K(+1.8%)
Dec 2014
$906.00 K(+18.9%)
$906.00 K(+8.1%)
Sep 2014
-
$838.00 K(+26.0%)
Jun 2014
-
$665.00 K(+36.8%)
Mar 2014
-
$486.00 K(-36.2%)
Dec 2013
$762.00 K(+91.9%)
$762.00 K(+102.1%)
Sep 2013
-
$377.00 K(+32.3%)
Jun 2013
-
$285.00 K(-9.8%)
Mar 2013
-
$316.00 K(-20.4%)
DateAnnualQuarterly
Dec 2012
$397.00 K(+3.4%)
$397.00 K(+55.1%)
Sep 2012
-
$256.00 K(+4.1%)
Jun 2012
-
$246.00 K(-63.2%)
Mar 2012
-
$669.00 K(+74.2%)
Dec 2011
$384.00 K(+207.2%)
$384.00 K(+93.9%)
Sep 2011
-
$198.00 K(+53.5%)
Jun 2011
-
$129.00 K(-29.1%)
Mar 2011
-
$182.00 K(+45.6%)
Dec 2010
$125.00 K(-43.4%)
$125.00 K(-33.9%)
Sep 2010
-
$189.00 K(+87.1%)
Jun 2010
-
$101.00 K(-40.6%)
Mar 2010
-
$170.00 K(-23.1%)
Dec 2009
$221.00 K(-50.6%)
$221.00 K(-55.4%)
Sep 2009
-
$496.00 K(-34.5%)
Jun 2009
-
$757.00 K(-6.0%)
Mar 2009
-
$805.00 K(+80.1%)
Dec 2008
$447.00 K(-25.6%)
$447.00 K(+179.4%)
Sep 2008
-
$160.00 K(-32.8%)
Jun 2008
-
$238.00 K(-48.6%)
Mar 2008
-
$463.00 K(-23.0%)
Dec 2007
$601.00 K(+76.8%)
$601.00 K(+4.9%)
Sep 2007
-
$573.00 K(+33.9%)
Jun 2007
-
$428.00 K(-26.7%)
Mar 2007
-
$584.00 K(+71.8%)
Dec 2006
$340.00 K(+15.3%)
$340.00 K(-18.3%)
Sep 2006
-
$416.00 K(+70.5%)
Jun 2006
-
$244.00 K(-52.9%)
Mar 2006
-
$518.00 K(+75.6%)
Dec 2005
$295.00 K(+43.2%)
$295.00 K(+81.0%)
Sep 2005
-
$163.00 K(-34.5%)
Jun 2005
-
$249.00 K(-33.2%)
Mar 2005
-
$373.00 K(+81.1%)
Dec 2004
$206.00 K(+24.1%)
$206.00 K(-39.4%)
Sep 2004
-
$340.00 K(+217.8%)
Jun 2004
-
$107.00 K(-84.4%)
Mar 2004
-
$686.70 K(+313.7%)
Dec 2003
$166.00 K(-45.2%)
$166.00 K(-51.4%)
Sep 2003
-
$341.60 K(-6.2%)
Jun 2003
-
$364.20 K(+44.8%)
Mar 2003
-
$251.60 K(-16.9%)
Dec 2002
$302.90 K(+28.2%)
$302.90 K(+32.1%)
Sep 2002
-
$229.30 K(-58.6%)
Jun 2002
-
$554.50 K(+169.8%)
Mar 2002
-
$205.50 K(-13.0%)
Dec 2001
$236.20 K
$236.20 K(-18.6%)
Sep 2001
-
$290.30 K(+30.5%)
Jun 2001
-
$222.40 K

FAQ

  • What is Galectin Therapeutics annual accounts payable?
  • What is the all time high annual accounts payable for Galectin Therapeutics?
  • What is Galectin Therapeutics annual accounts payable year-on-year change?
  • What is Galectin Therapeutics quarterly accounts payable?
  • What is the all time high quarterly accounts payable for Galectin Therapeutics?
  • What is Galectin Therapeutics quarterly accounts payable year-on-year change?

What is Galectin Therapeutics annual accounts payable?

The current annual accounts payable of GALT is $6.43 M

What is the all time high annual accounts payable for Galectin Therapeutics?

Galectin Therapeutics all-time high annual accounts payable is $6.43 M

What is Galectin Therapeutics annual accounts payable year-on-year change?

Over the past year, GALT annual accounts payable has changed by +$2.54 M (+65.32%)

What is Galectin Therapeutics quarterly accounts payable?

The current quarterly accounts payable of GALT is $2.79 M

What is the all time high quarterly accounts payable for Galectin Therapeutics?

Galectin Therapeutics all-time high quarterly accounts payable is $6.43 M

What is Galectin Therapeutics quarterly accounts payable year-on-year change?

Over the past year, GALT quarterly accounts payable has changed by +$114.00 K (+4.25%)